Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Salvage radiotherapy + short-term ADT vs apalutamide AAT after radical prostatectomy
2024-512023-37-00Phase 2Authorised
- Sponsor
- Ziekenhuis Aan De Stroom
- Start
- Jun 2024
- Modality
- Small Molecules, Peptides, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of goserelin, degarelix, leuprolide, triptorelin and apalutamide in prostate cancer (PCa) (2 arms), sponsored by Ziekenhuis Aan De Stroom. Primary endpoint: EPIC-26 sexual domain score at 9 months. Planned start Jun 2024; status: authorised.
02
Drugs
goserelindegarelixleuprolidetriptorelinapalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2024-512023-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512023-37-00.